HIV infection is one of the major global public health problem. Currently, among the specialists, an estimated 33 million people are infected with HIV worldwide. At present, six main classes of antiretroviral drugs exist, and almost all of them are used in antiretroviral therapy regimen in treatment-experienced as well as treatment-naive patients. Protein inhibitors are selective inhibitors of the cleavage of HIV-encoded gag-pol polyproteins. Darunavir, previously known as TMC-114, is a new, second-generation PI. Darunavir has high potency, genetic barrier and very good clinical and metabolic tolerance. In twice-daily dose darunavir is used as a rescue therapy in treatment-experienced patients. However, after ARTEMIS study, it was recently approved in first-line antiretroviral therapy for treatment-naïve HIV-infected patients.